vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
SCANSOURCE, INC.的季度营收约是BIOCRYST PHARMACEUTICALS INC的4.9倍（$766.5M vs $156.4M），BIOCRYST PHARMACEUTICALS INC同比增速更快（7.5% vs 2.5%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（19.6% vs 0.9%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
BCRX vs SCSC — 直观对比
营收规模更大
SCSC
是对方的4.9倍
$156.4M
营收增速更快
BCRX
高出4.9%
2.5%
两年增速更快
BCRX
近两年复合增速
0.9%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $766.5M |
| 净利润 | — | $16.5M |
| 毛利率 | — | 13.4% |
| 营业利润率 | 13.6% | 2.3% |
| 净利率 | — | 2.2% |
| 营收同比 | 7.5% | 2.5% |
| 净利润同比 | — | -3.3% |
| 每股收益（稀释后） | $0.00 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXSCSC
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $766.5M | ||
| Q3 25 | $159.4M | $739.6M | ||
| Q2 25 | $163.4M | $812.9M | ||
| Q1 25 | $145.5M | $704.8M | ||
| Q4 24 | $131.5M | $747.5M | ||
| Q3 24 | $117.1M | $775.6M | ||
| Q2 24 | $109.3M | $746.1M |
净利润BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $16.5M | ||
| Q3 25 | $12.9M | $19.9M | ||
| Q2 25 | $5.1M | $20.1M | ||
| Q1 25 | $32.0K | $17.4M | ||
| Q4 24 | $-26.8M | $17.1M | ||
| Q3 24 | $-14.0M | $17.0M | ||
| Q2 24 | $-12.7M | $16.1M |
毛利率BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 13.4% | ||
| Q3 25 | 98.6% | 14.5% | ||
| Q2 25 | 98.3% | 12.9% | ||
| Q1 25 | 96.9% | 14.2% | ||
| Q4 24 | 95.4% | 13.6% | ||
| Q3 24 | 97.3% | 13.1% | ||
| Q2 24 | 98.4% | 13.0% |
营业利润率BCRXSCSC
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 2.3% | ||
| Q3 25 | 18.6% | 3.5% | ||
| Q2 25 | 18.2% | 3.3% | ||
| Q1 25 | 14.6% | 3.2% | ||
| Q4 24 | -3.4% | 2.5% | ||
| Q3 24 | 6.6% | 2.3% | ||
| Q2 24 | 8.0% | 2.9% |
净利率BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 2.2% | ||
| Q3 25 | 8.1% | 2.7% | ||
| Q2 25 | 3.1% | 2.5% | ||
| Q1 25 | 0.0% | 2.5% | ||
| Q4 24 | -20.4% | 2.3% | ||
| Q3 24 | -12.0% | 2.2% | ||
| Q2 24 | -11.6% | 2.2% |
每股收益（稀释后）BCRXSCSC
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.75 | ||
| Q3 25 | $0.06 | $0.89 | ||
| Q2 25 | $0.02 | $0.87 | ||
| Q1 25 | $0.00 | $0.74 | ||
| Q4 24 | $-0.13 | $0.70 | ||
| Q3 24 | $-0.07 | $0.69 | ||
| Q2 24 | $-0.06 | $0.66 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $910.9M |
| 总资产 | $465.1M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXSCSC
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $83.5M | ||
| Q3 25 | $212.9M | $124.9M | ||
| Q2 25 | $260.0M | $126.2M | ||
| Q1 25 | $295.1M | $146.3M | ||
| Q4 24 | $320.9M | $110.5M | ||
| Q3 24 | $96.8M | $145.0M | ||
| Q2 24 | $78.4M | $185.5M |
股东权益BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $910.9M | ||
| Q3 25 | $-387.9M | $914.0M | ||
| Q2 25 | $-421.6M | $906.4M | ||
| Q1 25 | $-451.9M | $901.7M | ||
| Q4 24 | $-475.9M | $900.7M | ||
| Q3 24 | $-468.6M | $920.9M | ||
| Q2 24 | $-475.6M | $924.3M |
总资产BCRXSCSC
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.7B | ||
| Q3 25 | $446.4M | $1.7B | ||
| Q2 25 | $457.2M | $1.8B | ||
| Q1 25 | $480.0M | $1.7B | ||
| Q4 24 | $490.4M | $1.7B | ||
| Q3 24 | $491.3M | $1.8B | ||
| Q2 24 | $472.4M | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $30.8M |
| 自由现金流经营现金流 - 资本支出 | — | $28.9M |
| 自由现金流率自由现金流/营收 | — | 3.8% |
| 资本支出强度资本支出/营收 | — | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $30.8M | ||
| Q3 25 | $41.6M | $23.2M | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $-27.5M | $66.1M | ||
| Q4 24 | $-5.2M | $-6.2M | ||
| Q3 24 | $8.2M | $44.8M | ||
| Q2 24 | $-1.4M | — |
自由现金流BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | $28.9M | ||
| Q3 25 | $40.3M | $20.8M | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | $64.6M | ||
| Q4 24 | $-5.9M | $-8.2M | ||
| Q3 24 | $8.2M | $42.5M | ||
| Q2 24 | $-1.5M | — |
自由现金流率BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | 3.8% | ||
| Q3 25 | 25.3% | 2.8% | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | 9.2% | ||
| Q4 24 | -4.5% | -1.1% | ||
| Q3 24 | 7.0% | 5.5% | ||
| Q2 24 | -1.4% | — |
资本支出强度BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 0.3% | ||
| Q3 25 | 0.8% | 0.3% | ||
| Q2 25 | 0.1% | 0.3% | ||
| Q1 25 | 0.1% | 0.2% | ||
| Q4 24 | 0.5% | 0.3% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 0.1% | 0.2% |
现金转化率BCRXSCSC
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 1.87× | ||
| Q3 25 | 3.23× | 1.17× | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
